

Resource Summary Report

Generated by [dkNET](#) on Sep 11, 2026

Anti-Oct3/4-APC

RRID:AB_2653082

Type: Antibody

Proper Citation

Miltenyi Biotec Cat# 130-109-764, RRID:AB_2653082

Antibody Information

URL: http://antibodyregistry.org/AB_2653082

Proper Citation: Miltenyi Biotec Cat# 130-109-764, RRID:AB_2653082

Target Antigen: Oct3/4

Clonality: monoclonal

Comments: Discontinued: 7-2019; Target Distribution embryonic germ cells; target type Non-CD markers, REAfinity Antibodies, Cell signaling antibodies; tested applications MACS Flow Cytometry; quantity:

Antibody Name: Anti-Oct3/4-APC

Description: This monoclonal targets Oct3/4

Target Organism: mouse, human

Clone ID: REA622

Antibody ID: AB_2653082

Vendor: Miltenyi Biotec

Catalog Number: 130-109-764

Record Creation Time: 20231110T034451+0000

Record Last Update: 20260831T223941+0000

Ratings and Alerts

No rating or validation information has been found for Anti-Oct3/4-APC.

Warning: Discontinued: 2021

Discontinued: 7-2019; Target Distribution embryonic germ cells; target type Non-CD markers, REAfinity Antibodies, Cell signaling antibodies; tested applications MACS Flow Cytometry; quantity:

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Graffmann N, et al. (2021) Generation of a Crigler-Najjar Syndrome Type I patient-derived induced pluripotent stem cell line CNS705 (HHUUKDi005-A). Stem cell research, 51, 102167.

Martins S, et al. (2019) Fibroblast-derived integration-free iPSC line ISRM-NBS1 from an 18-year-old Nijmegen Breakage Syndrome patient carrying the homozygous NBN c.657_661del5 mutation. Stem cell research, 34, 101372.

Martins S, et al. (2018) Lymphoblast-derived integration-free ISRM-CON9 iPS cell line from a 75year old female. Stem cell research, 26, 76.

Martins S, et al. (2018) Lymphoblast-derived integration-free iPSC line AD-TREM2-3 from a 74?year-old Alzheimer's disease patient expressing the TREM2 p.R47H variant. Stem cell research, 30, 141.

Martins S, et al. (2018) Lymphoblast-derived integration-free iPSC line AD-TREM2-1 from a 67year-old Alzheimer's disease patient expressing the TREM2 p.R47H variant. Stem cell research, 29, 60.